Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.8% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price shot up 4.8% during trading on Tuesday . The company traded as high as $12.13 and last traded at $12.04. 31,787 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 244,637 shares. The stock had previously closed at $11.49.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MAZE. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 target price for the company. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Leerink Partners began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price objective for the company. Leerink Partnrs raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, Guggenheim began coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set a “buy” rating and a $19.00 price objective for the company. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and an average price target of $25.67.

Maze Therapeutics Trading Up 0.7 %

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.